

# Assess Ovarian Cancer Risk *Prior to Surgery.* Introducing **OVA1<sup>®</sup>plus**

## What is OVA1<sup>®</sup>plus?

For women with adnexal mass, **OVA1<sup>®</sup>plus** is a reflex process which first performs **OVA1<sup>®</sup>** and then performs **OVERA<sup>®</sup>** if the **OVA1<sup>®</sup>** result is in the *intermediate range*.



**Low Risk** is <4.4 (Postmenopausal) and <5.0 (Premenopausal) **Intermediate Risk** is 4.4-6.0 (Postmenopausal) and 5.0-7.0 (Premenopausal) **Markedly Elevated Risk** is >6.0 (Postmenopausal) and >7.0 (Premenopausal)

## What are the Benefits of OVA1<sup>®</sup>plus?

The combination of **OVA1<sup>®</sup>** and **OVERA<sup>®</sup>** helps you further stratify your patients risk of malignancy.

**Reduces** the falsely elevated rate in the **intermediate range** by

**OVER  
50%**

**Maintaining** the high rate of detection for risk of malignancy

**96%**  
**SENSITIVITY<sup>1</sup>**

(with clinical assessment)  
especially in **early stage** disease and all ethnicities

**Provides confidence** in negative results with a

**98%**  
**NEGATIVE<sup>1</sup>**


predictive value.

1. Bristow RE, Smith A, Zhang Z, et al., Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecol Oncol. 2013;128:252-259.

# OVA1<sup>®</sup> plus Biomarkers (OVA1<sup>®</sup> and OVERA<sup>®</sup>)




**OVA1<sup>®</sup>** is an FDA cleared multivariate index assay (MIA) that combines the results of five biomarkers and a proprietary algorithm to provide a malignancy risk index.



- 98% Negative Predictive Value
- 96% Sensitivity (with clinical assessment)
- Guideline support from ACOG, SGO & NCCN



**OVERA<sup>®</sup>** is an FDA cleared second generation multivariate index assay (MIA) that combines the results of five biomarkers and a proprietary algorithm to provide a malignancy risk index.



- OVERA<sup>®</sup> is performed when the OVA1<sup>®</sup> result is in the intermediate range
- 69% Specificity, 91% Sensitivity<sup>2</sup>
- Performing OVERA<sup>®</sup> in this range further stratifies risk and reduces the falsely elevated rate

2. Coleman RL, Herzog TJ, Chan DW, Munroe DG, Pappas TC, Smith A, Zhang Z, Wolf J. Validation of a Second-generation Multivariate Index Assay for Malignancy Risk of Adnexal Masses. Am J Obstet Gynecol. 2016 Mar 9.

OVA1<sup>®</sup> should be used in women >18yrs that have a pelvic mass to assess ovarian cancer risk prior to surgical treatment planning. It should be used in combination with clinical assessment and is not a screening test.

844.277.4721 [ASPIRALab.com](http://ASPIRALab.com)



© 2018 Vermillion. All rights reserved. The ASPIRA LABS and OVA1<sup>®</sup> logos are registered trademarks of Vermillion in the U.S. and other countries. Vermillion reserves the right to change this document at any time without notice and disclaims liability for editorial, pictorial or typographical errors.

